Sevenless Therapeutics ApS: Financial statements 2024
CVR: 43311999
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
Sevenless Therapeutics ApS (CVR 43311999) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK -260,403 and a net result of DKK -597,179 compared with DKK -103,456 the year before. Equity in the 2024 report amounted to DKK -485,242.
- Gross Profit
- DKK -260,403
- Profit/Loss
- DKK -597,179
- Equity
- DKK -485,242
- Total Assets
- DKK 12,070,480
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | - | -260K | -597K | -485K | 0 |
| 2023 | - | -692K | -103K | 112K | 0 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
Sevenless Therapeutics ApS has published its annual report for 2023. Gross profit came to DKK -691,735, and the net result was DKK -103,456.
About Sevenless Therapeutics ApS
Sevenless Therapeutics ApS is a Danish company of the type Anpartsselskab based in København N, founded in 2022. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Alasdair Naylor, Alexander Robert Leech and Neil Benson. The company is owned by Sevenless Therapeutics Limited. According to the 2025 annual report, the company had an average of 3 employees. In 2025, the company reported a gross profit of DKK -197,098 and a net result of DKK -159,621 compared with DKK -597,179 the year before. Equity in the 2025 report amounted to DKK -644,863.